MedPath

A monocentric, double-blind, randomized phase III clinical study to investigate the antimicrobial efficacy and local tolerability of an antiseptic (Stellisept mucosa, containing 0.1 % octenidine dihydrochloride) after a single application at the genital mucosa in comparison to a reference product (Octenisept®) in a panel of 44 healthy male and female volunteer

Conditions
antisepsis of genital mucous membranes
Registration Number
EUCTR2006-000063-28-DE
Lead Sponsor
BODE Chemie GmbH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
44
Inclusion Criteria

- male and female healthy volunteers
- 18-65 years of age
- informed consent
- negative pregnancy test
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- age under 18 or over 65
- pregnancy or lactating mother

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: demonstrate antiseptic efficacy of product;Secondary Objective: demonstrate local tolerability of product;Primary end point(s): antiseptic efficacy (reduction of bacterial load)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath